Roche cobas BRAF V600 Mutation Test
Roche Molecular Systems, Inc. · Decision date Nov 4, 2026
What did the FDA approve?
The FDA approved supplement S046 for Roche Molecular Systems' cobas BRAF V600 Mutation Test on November 4, 2026, under a Special (Immediate Track) review. The decision covers updates to hazard information on the product labeling for the cobas DNA Sample Preparation Kit, which is a component of the cobas KRAS Mutation Test, the cobas BRAF V600 Mutation Test, and the cobas EFGR Mutation Test, v2.0.
The supplement reason is recorded as a labeling change involving indications, instructions, shelf life, or trade name. The source statement does not specify which hazard wording changed, what new hazard information was added, or how the labeling text was revised. This supplement does not constitute a new approval of the entire test system; it addresses only the stated labeling update for the sample preparation kit component.
FDA approval order statement
Approval for updates to the hazard information on the product labeling for cobas DNA Sample Preparation Kit, a component of cobas KRAS Mutation Test, cobas BRAF V600 Mutation Test, and cobas EFGR Mutation Test, v2.0.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Pathology
- Decision date
- Nov 4, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P110020/S046
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P110020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P110020 · Original PMA
COBAS 4800 BRAF V600 MUTATION TEST
P110020/S046 received
Application receipt date recorded by FDA.
P110020/S045 · Related supplement
cobas BRAF V600 Mutation Test
P110020/S046 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P110020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Roche Molecular Systems, Inc. | PMA approval | Aug 17, 2011 | FDA | |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P110020/S046
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




